<DOC>
	<DOCNO>NCT01655758</DOCNO>
	<brief_summary>This study design compare 24-hour efficacy intra ocular pressure ( IOP ) drug act either aqueous humor production ( `` inflow drug '' ) aqueous humor outflow ( `` outflow drug '' ) human eye affect ocular hypertension virgin treatment . The enrolled patient expose , cross-over design , n = 2 aqueous suppressant n= 3 uveoscleral outflow enhancer , 24 hr IOP measure . It hypothesise outflow drug may offer good stable control IOP 24 hour .</brief_summary>
	<brief_title>24-hour Control Intraocular Pressure ( IOP ) Ocular Hypertension</brief_title>
	<detailed_description>( ) study design : Prospective , open label , investigator-masked clinical trial , cross-over design , eye treat , OD choose analysis ; ( b ) study population : patient , show ocular hypertension , never expose hypotensive treatment ( see inclusion exclusion criterion detail ) . ( c ) study drug : Timolol dorzolamide choose inflow drug . The three prostaglandin analogue ( PGA ) Latanoprost , travoprost bimatoprost choose outflow drug . ( ) study flow-chart : upon enrollment , patient initiate follow schedule : 60 day timolol 0.5 % bid , 60 day washout , 60 day timolol 0.5 % -dorzolamide 2 % fixed combination bid , 60 day washout , 60 day PGA1 , 60 day washout , 60 day PGA2 , 60 day washout , 60 day PGA3 . Patients assign PGAs accord sequence ( L-T-B ) randomly generate . Data collect baseline study phase ( i.e . active treatment washout ) ( e ) main efficacy outcome : change mean IOP ( respect baseline ) end study phase change IOP ( respect baseline ) different time point 24-hour phasing . IOP measure 8 a.m. , 11 a.m. , 3 p.m. , 6 p.m. 9 p.m. mean Goldmann applanation tonometry slit lamp . At midnight , 2 a.m. 6 a.m. Tonopen supine position use . ( f ) statistic : analysis co-variance ( ANCOVA ) pair sample Bonferroni correction adopt . A minimum sample size 51 patient need minimal expect difference mean IOP inflow outflow drug = 2.5 mmHg , estimate pool variance = 4 , power = 90 % alpha probability = 5 % .</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Ocular Hypertension</mesh_term>
	<mesh_term>Latanoprost</mesh_term>
	<mesh_term>Dorzolamide</mesh_term>
	<mesh_term>Bimatoprost</mesh_term>
	<mesh_term>Travoprost</mesh_term>
	<mesh_term>Timolol</mesh_term>
	<criteria>IOP &gt; 22 mmHg &lt; 30 mmHg least three reading separate day , Open angle gonioscopy , CCT &gt; 550 , optic disk classify `` within normal limit '' Moorfields Regression analysis , HRTII , normal visual field ( standard achromatic perimetry , Humphrey Field Analyzer , 24/2 SITA standard ) , Age &gt; 40 &lt; 70 year , refraction 5 + 2 dyopters , best correct visual acuity well 0.2 LogMAR , PEX PDS ocular comorbidiities refractive problem and/or mild dry eye history diabetes treatment systemic beta blocker steroids previous treatment ocular hypotensive drug</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>glaucoma</keyword>
	<keyword>24-hour IOP</keyword>
	<keyword>outflow drug</keyword>
	<keyword>inflow drug</keyword>
</DOC>